Impact of omalizumab in children from a middle‐income country with severe therapy‐resistant asthma: A real‐life study

Abstract

In this retrospective report, the use of omalizumab in Brazilian children with STRA significantly improved disease control, decreased hospitalizations, and allowed suspension of continuous oral corticosteroids.

New perspectives of childhood asthma treatment with biologics

“…Pitrez et al also reported an improvement in 14 severely allergic children (mean age: 11.9 years), with nine having been on daily OCS treatment for 27 ± 16 months. Hospitalization for exacerbations was reduced by 70%, and OCS could be stopped in eight children …”

“…Hospitalization for exacerbations was reduced by 70%, and OCS could be stopped in eight children. 23…”

Impacto clínico del tratamiento con omalizumab en niños con asma grave. Reporte de una experiencia local

“…El control clínico, las exacerbaciones e internaciones constituyen los parámetros en los que el tratamiento con omalizumab ha mostrado mayor impacto. [12][13][14][15][22][23][24][25][26] El principal resultado de esta serie fue alcanzar el control total del asma referido por los propios pacientes, según el TCA. Diferentes ensayos clínicos en pediatría han demostrado la eficacia del fármaco en las tasas de exacerbaciones, con un efecto menor en el control de síntomas, observado, especialmente, en niños de 6 a 11 años de edad.…”

Pediatric Pulmonology year in review 2017: Part 3

“…22 Improvement in FEV1 was shown for mometasone furoate at all three doses tested (50, 100, and 200 mcg) given for 12 weeks, compared to placebo, and the drug was well tolerated with no safety concerns. Pitrez et al 23 infants with moderate to severe respiratory distress syndrome to either nCPAP or nHFOV. 30 They determined that infants receiving nHFOV had a significantly lower need for invasive mechanical ventilation in this population, suggesting that nHFOV should be considered in the NICU to prevent the need for intubation.…”

“…Improvement in FEV1 was shown for mometasone furoate at all three doses tested (50, 100, and 200 mcg) given for 12 weeks, compared to placebo, and the drug was well tolerated with no safety concerns. Pitrez et al evaluated the effectiveness of at least 6 months of omalizumab treatment in children with severe, treatment‐resistant asthma, and demonstrated significant improvement in hospitalizations and need for oral corticosteroids. The Preventative Omalizumab or Step‐up Therapy for Severe Fall Exacerbations (PROSE) study showed that omalizumab treatment significantly reduced rhinovirus infection and symptoms such as rhinitis, sneezing, and cough …”